ArticleClinical ophthalmology (Auckland, N.Z.)2021

A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease.

David McMullin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.